ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Articles tagged "Anticoagulation"

  • 2020 American Transplant Congress

    Utilization of Direct Acting Oral Anticoagulation in Solid Organ Transplant Patients: A National Survey of Institutional Practices

    D. Pierce1, A. Lichvar1, D. Salerno2, P. Klem3, G. Waldman4, J. M. Park5

    1University of Illinois at Chicago, Chicago, IL, 2NewYork-Presbyterian Hospital, New York, NY, 3University of Colorado Hospital, Aurora, CO, 4Massachusetts General Hospital, Boston, MA, 5University of Michigan, Ann Arbor, MI

    *Purpose: The safety and efficacy of direct acting oral anticoagulants (DOACs) and reversal strategies are not well established in the solid organ transplant population. This…
  • 2020 American Transplant Congress

    Evaluation of Apixaban Usage in Solid Organ Transplant Patients with Renal Impairment

    L. Rakouki, R. Yau, C. Tunwar

    Pharmacy, CHI St. Luke's Health-Baylor St. Luke's Medical Center, Houston, TX

    *Purpose: There remains a gap in the literature for apixaban dosing recommendations for treatment of deep vein thrombosis (DVT) or pulmonary embolism (PE) in special…
  • 2020 American Transplant Congress

    The Effects of Rivaroxaban and Apixaban on Tacrolimus Pharmacokinetics

    A. C. Scheibner1, C. Franco-Martinez1, E. Kincaide1, R. Hall1, C. Long2

    1Pharmacotherapy Division, College of Pharmacy, The University of Texas at Austin, University Health System, The University of Texas Health Science Center at San Antonio, San Antonio, TX, 2Feik School of Pharmacy, University of the Incarnate Word, University Health System, The University of Texas Health Science Center at San Antonio, San Antonio, TX

    *Purpose: To clarify the pharmacokinetic impact of rivaroxaban (RIVA) and apixaban (APIX) on tacrolimus (TAC) concentrations.*Methods: Solid organ transplant recipients 18-years or older who were…
  • 2019 American Transplant Congress

    Anti-Xa Level Monitoring for Treatment Dose Enoxaparin in Liver/Intestine Transplant Recipients

    J. Sullivan, J. Jebrock, J. Revollo, M. Perez, J. Garcia, T. Beduschi

    Jackson Memorial Hospital, Miami, FL

    *Purpose: Evaluate the use of anti-Xa levels in therapeutic enoxaparin dosing in liver/intestine transplant recipients.*Methods: A single-center retrospective chart review was conducted on liver/intestine transplant…
  • 2019 American Transplant Congress

    Direct Oral Anticoagulants: An Evaluation of the Safety and Efficacy in Solid Organ Transplant Recipients

    T. Pasley, A. Logan, A. Brueckner, L. Bowman, A. Silverman, A. Rumore

    Tampa General Hospital, Tampa, FL

    *Purpose: The use of direct oral anticoagulants (DOACs) has not been fully adopted by the solid organ transplant (SOT) community due to factors including, fluctuating…
  • 2019 American Transplant Congress

    The Comparative Safety and Efficacy of Direct Acting Oral Anticoagulants Relative to Warfarin Following Liver Transplantation

    A. Santeusanio, A. Weinberg, T. Schiano

    Mount Sinai Hospital, New York, NY

    *Purpose: This study describes the comparative safety and efficacy of direct acting oral anticoagulants (DOACs) relative to warfarin following liver transplantation, at a large academic…
  • 2019 American Transplant Congress

    Idarucizumab For The Reversal Of Dabigatran In Patients Undergoing Heart Transplantation

    J. Van Keer1, T. Vanassche1, W. Droogne1, S. Rex2, F. Rega3, J. Van Cleemput1, P. Verhamme1, M. Naesens4

    1Cardiology, University Hospitals Leuven, Leuven, Belgium, 2Anesthesiology, University Hospitals Leuven, Leuven, Belgium, 3Cardiovascular Surgery, University Hospitals Leuven, Leuven, Belgium, 4Nephrology, University Hospitals Leuven, Leuven, Belgium

    *Purpose: Atrial fibrillation is common among patients with advanced heart failure who are listed for transplantation. Idarucizumab is a monoclonal antibody fragment that was developed…
  • 2019 American Transplant Congress

    Variables Associated with Intracardiac Thrombus during Orthotopic Liver Transplant: A Retrospective Single-Center Study

    M. Groose1, J. Mezrich2, L. Hammel1

    1Department of Anesthesiology, University of Wisconsin, Madison, WI, 2Department of Surgery, University of Wisconsin, Madison, WI

    *Purpose: Intracardiac thrombus (ICT) is an intraoperative complication during orthotopic liver transplantation (OLT) with high mortality. Patients with end stage liver disease have compromised coagulation…
  • 2019 American Transplant Congress

    Anticoagulation in Post-Liver Transplant Recipients with Portal Vein Thrombosis

    L. Schumacher1, L. Lindberg1, D. Alonso2, R. Gilroy3, J. Krong4, L. Dong4, S. LeCorchick1

    1Department of Pharmacy, Intermountain Medical Center, Murray, UT, 2Transplant Surgery, Intermountain Medical Center, Murray, UT, 3Transplant Hepatology, Intermountain Medical Center, Murray, UT, 4Department of Transplant, Intermountain Medical Center, Murray, UT

    *Purpose: The purpose of this study is to compare safety and efficacy outcomes in liver transplant recipients with portal vein thrombosis (PVT) at the time…
  • 2019 American Transplant Congress

    Impact of Prolonged Venous Thromboembolism Prophylaxis on 30-Day Hemostatic Outcomes Following Kidney Transplantation in Patients with Hypercoagulable Risk Factors

    V. Behbahani, A. Santeusanio, S. Ames, R. Shapiro

    Mount Sinai Hospital, New York, NY

    *Purpose: A number of hypercoagulable states have been identified through laboratory testing that place patients at greater risk for thrombosis; however, the appropriate management of…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 7
  • Next Page »

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences